Previous Close | 0.3485 |
Open | 0.5299 |
Bid | N/A x N/A |
Ask | N/A x N/A |
Day's Range | 0.3233 - 0.5299 |
52 Week Range | 0.3020 - 1.0450 |
Volume | |
Avg. Volume | 565 |
Market Cap | 2.341M |
Beta (5Y Monthly) | -1.38 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -0.1700 |
Earnings Date | Mar 29, 2024 - Apr 01, 2024 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | Mar 02, 2007 |
1y Target Est | N/A |
Mosaic ImmunoEngineering, Inc. ("Mosaic" or the "Company"), (OTCQB:CPMV), a development-stage biotechnology company focused on the development of novel immunotherapies to treat and prevent cancer, today announced that the US Patent and Trademark Office (USPTO) has issued an additional patent to protect the technology behind Mosaic's lead immuno-oncology product candidate, MIE-101.